Sunday, November 15, 2026

Global Central Banks Reverse Course on Rates as Iran Conflict Drives Energy Prices

The Federal Reserve and European Central Bank are signaling rate hikes through 2026, abandoning dovish stances from months ago as Iran conflict pushes energy prices higher. Market expectations have shifted dramatically, with 52% probability now priced for rate increases versus December's anticipation of two cuts in 2025.

This article was written by AI. Built from the source documents listed below. How we work

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
Global Central Banks Reverse Course on Rates as Iran Conflict Drives Energy Prices
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Central banks across developed economies are pivoting to potential rate hikes through 2026 as the Iran conflict drives energy prices higher and reignites inflation concerns.1 The shift marks a sharp reversal from dovish expectations that dominated markets just months ago.

ECB policymaker Pierre Wunsch stated that "an ECB rate hike in April is not out of the question" if evidence emerges that the Iran war will persist and drive inflation higher.2 Fellow policymaker Madis Muller echoed concerns, noting the ECB cannot rule out rate changes as early as April if energy prices remain elevated.3

Market expectations have undergone a dramatic transformation across Atlantic markets. December CME FedWatch polling showed traders anticipating two U.S. interest rate cuts in 2025.4 Today, only 0.2% of traders expect rates to fall to 3.25-3.5% by end of 2026. Markets instead price in a 52% probability of rate hikes.4

The policy pivot reflects central banks' concerns that geopolitical energy shocks could derail inflation progress across major economies. Richmond Fed President Thomas Barkin has signaled the Federal Reserve's readiness to maintain restrictive policy longer than previously anticipated.5

Central banks globally are accelerating gold purchases as reserve diversification intensifies amid geopolitical uncertainty.1 The trend underscores broader concerns about financial stability and currency risk in an environment of elevated energy prices and geopolitical tensions.

For global investors, the implications are clear: the era of anticipated rate cuts has ended. Bond yields are climbing across developed markets as monetary policy expectations reprice. Equity valuations face pressure from higher discount rates. The energy-driven inflation shock is forcing central banks to prioritize price stability over growth support, a stance that could persist well into 2026 if the Iran conflict remains unresolved.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleNasdaq· March 27, 2026
    Canadian Stocks Edge Higher As Markets Turn Cautious Amid Middle East Escalation
  2. [2]News articleNasdaq· March 27, 2026
    Dollar Advances as Iran War Rages
  3. [3]News articleNasdaq· March 27, 2026
    Dollar Gains on Concerns Over a Protracted Iran War
  4. [4]News articleSg· March 30, 2026
    Dollar holds firm as risk of protracted Middle East war saps sentiment
  5. [5]News articleYahoo Finance· April 4, 2026
    Goldman Sachs has blunt message on gold price for rest of 2026
  6. [6]News articleNasdaq· March 28, 2026
    Look Beyond Skyrocketing Gas Prices! If a Stock Market Crash Takes Shape Under President Donald Trump, the Fed Is Likely to Be the Catalyst.
  7. [7]News articleSeeking Alpha· March 27, 2026
    Philadelphia Fed's Anna Paulson sees long-run federal funds rate at about 3.1%
  8. [8]News articleNasdaq· April 3, 2026
    Retail Investors Are Getting Cautious: Is That Actually a Contrarian Buy Signal?
  9. [9]News articleNasdaq· March 27, 2026
    Stocks Fall and Bond Yields Rise on Concern About a Protracted Iran War
  10. [10]News articleNasdaq· March 27, 2026
    Stocks Falter as Iran War Pushes Energy Prices and Bond Yields Higher
  11. [11]News articleNasdaq· March 27, 2026
    Stocks Settle Sharply Lower on Fears Iran War is Escalating
  12. [12]News articleNasdaq· March 31, 2026
    Stocks Surge on Signs the US and Iran Seek to End War

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

In this story · Knowledge Files

Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com